BB-12 probiotic yogurt trial in children on antibiotics
494 fecal samples from children prescribed antibiotics for respiratory infections, studied longitudinally in a randomized, placebo-controlled, double-blinded trial testing BB-12-supplemented yogurt versus control yogurt for preventing antibiotic-associated diarrhea. machine-written summary
494 samples · 494 runs · US · Child · 2024 · 14.39 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 988 sample values (subject id, timepoint) |
| ✓ Abstract / description | 494 sample values (antibiotic exposure) |
| ✓ Full text | 494 sample values (country) · PMC13000283 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Antibiotic given as the study intervention (incl. eradication therapy Probiotic (live microorganisms; single strain or mixture) design randomized_controlled_trial · population healthy_control · BB-12 probiotic yogurt vs control yogurt, with prescribed antibiotics
“randomized, placebo-controlled, double-blinded study” — abstract:41699149 (study level; per-sample arms are in the intervention column below)
longitudinal
101 of 101 people sampled more than once (494 samples; median 5, up to 5 per person) · follow-up median 30 d (max 30 d) · median interval between samples 7 d (time from timepoint labels). Schedule stated by the source: “stool at day 0, 7, 14, 21, 30 (study timeline Day 0 to Day 180)” (time origin: intervention_start); stated follow-up 6 mo.
Each row is one person (36 shown of 101); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 439 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 494 | 100% | ||||
| country | 494 | 100% | 494 | |||
| health_condition | 0 | 0% | ||||
| subject_id | 494 | 100% | 494 | |||
| antibiotic_exposure | 494 | 100% | 494 | |||
| timepoint_label | 494 | 100% | 494 |
- Probiotic intervention not beneficial to prevent antibiotic-associated diarrhea in absence of antibiotic-induced microbiome disruption. 2026 PMID 41699149 PMC13000283 own_data
Archive description
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. One of the most common indications for probiotic treatment is the prevention of antibiotic-associated diarrhea (AAD). Unfortunately, many probiotic products used for AAD are not supported by rigorous independent research, and often results in non-evidence-based usage. The overarching objective is to move research forward for the most well-studied Bifidobacterium strain. The primary aim is to test the efficacy of high dose, BB-12-supplemented yogurt in preventing AAD, compared to yogurt without BB-12, in children receiving antibiotics. Other aims are to further assess the safety of yogurt supplemented with BB-12, and to carry out longitudinal community structure and gene expression analysis of fecal microbiota to evaluate the impact of high dose BB-12 in a pediatric population receiving antibiotics. The microbiota includes hundreds of species, and its disruption is hypothesized to be an important factor in the development of AAD.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of child by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_child_over_36m”
- body site study.description · “expression analysis of fecal microbiota to evaluate”
- body site external_curation.infant_catalog · “body_site_call stool”
- life stage external_curation.infant_catalog · “infant triage reason_code age_child_over_36m”
- life stage study.title · “Yogurt For Healthy Children on Antibiotics (PLAY”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN40075873 | antibiotic_exposure | yes | R4 | 0.50 | paper.abstract | children who were prescribed antibiotics for acute outpatient upper respiratory illnesses |
| SAMN40075873 | country | US | R3 | 0.70 | paper.fulltext.methods | Georgetown University Institutional Review Board |
| SAMN40075873 | subject_id | 103A | R1 | 0.85 | biosample.attribute:isolate | participant 103A study day 0 |
| SAMN40075873 | timepoint_label | study day 0 | R1 | 0.85 | biosample.attribute:isolate | participant 103A study day 0 |
Sequencing
494 runs over 494 samples · mean 14.70 Gbp per run (median 14.39 Gbp, total 7,262.17 Gbp; 494 runs with a base count) · layout PAIRED 494 · platform ILLUMINA 494 · models Illumina NovaSeq 6000 (494) · 89% of runs with a Sandpiper profile · first public 2024-02-26
Authors (11)
Merenstein D first · Grant-Beurmann S · Sanders ME · Tan T · Burke B · Kumar A · Herbin-Smith K · Sparenborg J · D'Amico F · Roberts B · Fraser C last
Downloads
PRJNA1079705.csv.gz (13.3 KB) · parquet (85.6 KB) — all 494 samples, every field with route and confidence · PRJNA1079705_determinations.csv.gz (16.5 KB) — 1,976 evidence rows